NEW ZEALAND EQUITY RESEARCH | FOOD, BEVS, & AGRI | AQUACULTURE 22 FEBRUARY 2021

New Zealand King Salmon

1H21 Preview — Taking the Temperature

guy.hooper@forsythbarr.co.nz +64 4 495 5255

OUTPERFORM 2



Market conditions remain tough and we expect New Zealand King Salmon (NZK) to report a subdued 1H21 result on Wednesday, 24 February 2021. We expect investor focus will be on export channel performance, given the fluid backdrop of COVID-19 restrictions in key markets. NZK's previous guidance commentary indicated FY21 Operating EBITDA was unlikely to exceed FY20 (FY20 NZ\$25m, FY21E NZ\$22m), however, NZK has since changed its balance date to year end January (previously June) to better align with fish performance.

NZX Code	NZK	Financials: Jun/	20A	21E	22E	23E	Valuation (x)	20A	21E	22E	23E
Share price	NZ\$1.56	NPAT* (NZ\$m)	18.0	7.4	15.8	19.3	PE	12.0	29.3	13.7	11.3
Target price	NZ\$2.65	EPS* (NZc)	13.0	5.3	11.4	13.9	EV/EBIT	13.9	19.6	10.4	8.8
Risk rating	Medium	EPS growth* (%)	58.1	-58.8	n/a	21.9	EV/EBITDA	9.0	11.3	7.2	6.3
Issued shares	139.0m	DPS (NZc)	2.0	3.0	5.0	6.0	Price / NTA	1.6	1.6	1.3	1.2
Market cap	NZ\$217m	Imputation (%)	100	100	100	100	Cash div yld (%)	1.3	1.9	3.2	3.8
Avg daily turnover	46.6k (NZ\$81k)	*Based on normalis	ed profit	:s			Gross div yld (%)	1.8	2.7	4.5	5.3

Key areas of focus at NZK's 1H21 result

- Export market performance High COVID-19 case numbers and revolving lockdowns in key export markets continue to suppress demand. NZK has made noticeable progress in its push into USA retail markets, announcing new hires and new
- Prices NZK has a track record of delivering price gains. We understand NZK has not undertaken any price changes on its export product, but elevated promotional activity in domestic retail, in combination with unfavourable mix change, is likely to weigh on average price achieved.
- Water temperatures and fish performance Warming waters have proved a challenge for NZK in recent years. The 2020–2021 summer to date has been cooler than prior periods in the high-risk areas; however, the marine environment forecast appears challenging.
- Farm consents and open ocean NZK operates a number of under performing locations, we look for an update on a possible relocation of these consents. In 2019 NZK applied for its first open ocean site, which would eventually allow for ~8,000MT of production over an 18 month cycle. A hearing on its application is due to occur in May 2021.

1H21 conference call — 12:00pm on Wednesday, 24 February 2021

Dial in details: New Zealand 0800 122 136, Conference ID: 10011811.

Figure 1. 1H21E result expectations

	1H20	1H21E	% change
Revenue	84.2	74.6	-11%
EBITDA	33.9	13.6	-60%
EBIT	29.5	8.9	-70%
Normalised NPAT	20.8	5.6	-73%
EPS (cps)	15.0	4.0	-73%
DPS (cps)	2.0	1.5	-25%

Source: Forsyth Barr analysis

☼ FORSYTH BARR

New Zealand King Salmon (NZK)

Priced as at 22 Feb 2021 (NZ\$)					1.56						
12-month target price (NZ\$)*					2.65	Spot valuations (NZ\$)					
Expected share price return					69.9%	1. DCF					2.81
Net dividend yield					2.8%	2. Comparative multiples					2.40
Estimated 12-month return					72.6%	3. Market multiple					n/a
Estimated 12 month return					72.070	o. Market multiple					11/4
Key WACC assumptions						DCF valuation summary (NZ\$m)					
Risk free rate					1.30%	Total firm value					447
Equity beta					1.01	(Net debt)/cash					(31)
WACC					6.4%	Less: Capitalised operating leases					
Terminal growth					2.0%	Value of equity					416
Profit and Loss Account (NZ\$m)	2019A	2020A	2021E	2022E	2023E	Valuation Ratios	2019A	2020A	2021E	2022E	2023E
Sales revenue	172.6	155.3	160.9	204.4	219.2	EV/EBITDA (x)	8.6	8.8	11.1	7.1	6.2
Normalised EBITDA	25.2	26.5	22.0	34.2	39.0	EV/EBIT (x)	11.5	13.7	19.3	10.2	8.7
Depreciation and amortisation	(6.2)	(9.4)	(9.4)	(10.4)	(11.1)	PE (x)	19.0	12.0	29.3	13.7	11.3
Normalised EBIT	18.9	17.1	12.6	23.8	27.9	Price/NTA (x)	1.8	1.6	1.6	1.3	1.2
Net interest	(1.1)	(1.7)	(2.3)	(1.9)	(1.2)	Free cash flow yield (%)	-1.5	-5.5	2.8	5.5	10.2
Associate income	0	0	0	0	0	Net dividend yield (%)	3.2	1.3	1.9	3.2	3.8
Tax	4.4	6.9	2.9	6.1	7.5	Gross dividend yield (%)	4.5	1.8	2.7	4.5	5.3
Minority interests	0	0	0	0	0	, , ,					
Normalised NPAT	11.4	18.0	7.4	15.8	19.3	Capital Structure	2019A	2020A	2021E	2022E	2023E
Abnormals/other	0	0	0	0	0	Interest cover EBIT (x)	17.3	9.9	5.4	12.7	23.6
Reported NPAT	11.4	18.0	7.4	15.8	19.3	Interest cover EBITDA (x)	23.0	15.3	9.4	18.2	32.9
Normalised EPS (cps)	8.2	13.0	5.3	11.4	13.9	Net debt/ND+E (%)	5.2	14.4	14.2	10.2	5.5
DPS (cps)	5.0	2.0	3.0	5.0	6.0	Net debt/EBITDA (x)	0.4	1.2	1.4	0.8	0.3
Вт 3 (срз)	3.0	2.0	0.0	5.0	0.0	Net debt/ LBTT DA (X)	0.4	1.2	1.4	0.0	0.5
Growth Rates	2019A	2020A	2021A	2022A	2023A	Key Ratios	2019A	2020A	2021E	2022E	2023E
Revenue (%)	7.7	-10.0	3.6	27.0	7.2	Return on assets (%)	8.5	6.2	4.6	7.8	9.0
EBITDA (%)	-3.8	5.3	-17.1	55.7	14.0	Return on equity (%)	6.7	9.8	4.1	7.4	8.3
EBIT (%)	-10.1	-9.6	-26.3	88.7	17.3	Return on funds employed (%)	9.5	7.0	5.2	8.8	10.1
Normalised NPAT (%)	-30.5	58.6	-58.8	>100	21.9	EBITDA margin (%)	14.6	17.1	13.7	16.7	17.8
Normalised EPS (%)	-30.6	58.1	-58.8	>100	21.9	EBIT margin (%)	11.0	11.0	7.8	11.7	12.7
Ordinary DPS (%)	0.0	-60.0	50.0	66.7	20.0	Capex to sales (%)	8.2	10.4	6.4	8.5	6.9
						Capex to depreciation (%)	228	172	110	167	136
Cash Flow (NZ\$m)	2019A	2020A	2021E	2022E	2023E	Imputation (%)	100	100	100	100	100
EBITDA	25.2	26.5	22.0	34.2	39.0	Pay-out ratio (%)	61	15	56	44	43
Working capital change	(8.7)	(13.6)	(0.2)	3.3	7.0	,					
Interest & tax paid	(5.5)	(8.7)	(5.4)	(8.2)	(8.9)	Operating Performance	2019A	2020A	2021E	2022E	2023E
Other	0	0	0	0	0	Revenue split by market (NZ\$m)					
Operating cash flow	10.9	4.2	16.4	29.3	37.1	Domestic	79.8	66.7	69.1	88.1	94.2
Capital expenditure	(14.2)	(16.1)	(10.3)	(17.3)	(15.0)	Export	92.9	88.6	91.8	116.4	125.0
(Acquisitions)/divestments	0.0	0.0	0	0	0	Total	172.6	155.3	160.9	204.4	219.2
Other	0.0	(1.4)	(1.0)	(1.0)	(1.0)		1,2.0	133.3	100.7	257.7	217.2
Funding available/(required)	(3.2)	(13.3)	5.1	11.0	21.0	Revenue split by market (%)					
Dividends paid	(7.1)	(6.9)	(4.2)	(6.9)	(8.3)	Domestic Domestic	46%	43%	43%	43%	43%
Equity raised/(returned)	0.0	0.0	0	0	0	Export	54%	57%	57%	57%	57%
(Increase)/decrease in net debt	(10.4)	(20.2)	0.9	4.0	12.7	Export	3470	3770	3770	3770	3770
(6455), 4551 6455 1151 4521	(20)	(20.2)	0.7			Revenue split by country (NZ\$m)					
Balance Sheet (NZ\$m)	2019A	2020A	2021E	2022E	2023E	New Zealand	79.8	66.0	69.1	88.1	94.2
Working capital	17.8	33.5	33.9	30.8	24.0	North America	58.5	58.4	58.9	77.7	83.3
Fixed assets	51.8	60.5	63.5	72.5	78.5	Australia	11.9	9.3	11.2	14.3	15.3
Intangibles	46.8	47.9	48.1	48.4	48.6	Japan	5.9	5.3	5.0	6.1	6.6
Right of use asset	0	4.6	4.6	4.6	4.6	Europe	3.1	3.6	2.9	3.7	4.0
Other assets	82.9	105.7	99.5	120.5	126.3	Other	13.5	12.7	13.7	14.5	15.9
Total funds employed	199.3	252.2	249.7	276.7	282.0	Total	172.6	155.3	160.9	204.4	219.2
Net debt/(cash)	9.2	31.0	30.1	26.1	13.4	. C.Cai	1/2.0	133.3	100.7	204.4	217.2
Lease liability	9.2	3.3		3.5	3.7	Harvest volume (MT)	7,931	7 22/	g E00	Q E00	9,000
•			3.4			Harvest volume (MT)		7,336	8,500	8,500	9,000
Other liabilities	21.4	33.6	33.6 182.5	33.6	33.6	Average realised price (NZ\$/kg)	23.01	24.99	23.80	24.33	24.64
Shareholder's funds Minority interests	168.8 0	184.3	182.5 0	213.5 0	231.4 0						
Minority interests		0									
* Forsyth Park target prices reflect vol	199.3	252.2	249.7	276.7	282.0						

^{*} Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend


FORSYTH BARR

Water temperature data

The optimal SST (sea surface temperature) range for fish performance is 12°C to 17°C, with days over 17°C a key driver of higher mortalities (alongside low oxygen, disease, and stress).


FY18 and FY19 had as many as 18 and 19 weeks (respectively) with temperatures over 17° C in the period December-April. NZK annual mortalities spiked to 20% and 23% in those years, from 8.5% in FY17. Mortalities reduce both the current and following year harvests, as well as increase cost per tonne. Temperatures to date remain consistent with our mortality forecast (FY21E mortality rate 14%). As a guide a +2% increase in mortality would have a c. -6% impact on forecast EBITDA.

Figure 2. Water temperature — Tory Channel



Source: NZK, Forsyth Barr analysis

Figure 4. Water temperature — Pelorus




Source: NZK, Forsyth Barr analysis

Figure 3. Water temperature — Queen Charlotte



Source: NZK, Forsyth Barr analysis


Figure 5. Indicative fish mortality seasonality



Source: NZK, Forsyth Barr analysis

FORSYTH BARR

Figure 6. Price performance



Source: Forsyth Barr analysis

Figure 7. Substantial shareholders

Shareholder	Latest Holding
Oregon Group	40.2%
China Resources	10.0%
New Zealand Superannuation Fund	6.5%


Source: NZX, Forsyth Barr analysis, NOTE: based on SPH notices only

Figure 8. International valuation comparisons

Company	Code	Price	Mkt Cap	PE		EV/EBITDA		EV/EBIT		Cash Yld	
(metrics re-weighted to reflect NZK's	(m)	2021E	2022E	2021E	2022E	2021E	2022E	2022E			
New Zealand King Salmon	NZK NZ	NZ\$1.56	NZ\$217	29.3x	13.7x	11.3x	7.2x	19.6x	10.4x	3.2%	
SANFORD*	SAN NZ	NZ\$4.50	NZ\$421	16.3x	11.1x	8.6x	6.8x	14.2x	10.2x	4.5%	
HUON AQUACULTURE GROUP	HUO AT	A\$2.61	A\$287	<0x	21.0x	25.0x	9.6x	<0x	23.1x	1.4%	
TASSAL GROUP	TGR AT	A\$3.22	A\$680	12.8x	10.6x	8.3x	7.2x	13.3x	10.9x	4.8%	
MOWI ASA	MOWI NO	€193.15	€99,880	>50x	>50x	>75x	>75x	>75x	>75x	0.4%	
SALMAR ASA	SALM NO	kr535.40	kr60,661	24.9x	20.0x	15.9x	13.5x	19.8x	16.5x	3.9%	
DELEGAT GROUP *	DGL NZ	NZ\$14.65	NZ\$1,482	22.9x	19.9x	14.7x	13.1x	17.1x	15.1x	1.3%	
SCALES*	SCL NZ	NZ\$4.80	NZ\$682	21.2x	19.0x	9.5x	8.6x	13.4x	11.9x	4.5%	
COMVITA*	CVT NZ	NZ\$3.25	NZ\$227	21.2x	17.2x	11.5x	10.5x	20.6x	17.3x	1.5%	
			Compco Average:	19.9x	17.0x	13.4x	9.9x	16.4x	15.0x	2.8%	
EV = Current Market Cap + Actual Net Debt			NZK Relative:	47%	-19%	-16%	-27%	20%	-31%	15%	


Source: *Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (NZK) companies fiscal year end

Figure 9. Consensus EPS momentum (NZ\$)



Source: Forsyth Barr analysis

Figure 10. One year forward PE (x)



Source: Forsyth Barr analysis

FORSYTH BARR

Analyst certification: The research analyst(s) primarily responsible for the preparation and content of this publication ("Analysts") are named on the first page of this publication. Each such Analyst certifies (other than in relation to content or views expressly attributed to another analyst) that (i) the views expressed in this publication accurately reflect their personal views about each issuer and financial product referenced and were prepared in an independent manner, including with respect to Forsyth Barr Limited and its related companies; and (ii) no part of the Analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that Analyst in this report.

Analyst holdings: The following Analyst(s) have a threshold interest in the financial products referred to in this publication: N/A. For these purposes, a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser.

Ratings distributions: As at 19 Feb 2021, Forsyth Barr's research ratings were distributed as follows:

OUTPERFORM
46.2%

NEUTRAL
UNDERPERFORM
46.2%

17.3%

Forsyth Barr's research ratings are OUTPERFORM, NEUTRAL, and UNDERPERFORM. The ratings are relative to our other equity security recommendations across our New Zealand market coverage and are based on risk-adjusted Estimated Total Returns for the securities in question. Risk-adjusted Estimated Total Returns are calculated from our assessment of the risk profile, expected dividends and target price for the relevant security.

Disclosure: Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. Forsyth Barr confirms no inducement has been accepted from the issuer(s) that are the subject of this publication, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the issuer(s) being researched.

Investment banking engagements: Other than confidential engagements, Forsyth Barr has not within the past 12 months been engaged to provide investment banking services to the issuer that is the subject of this publication. For information about whether Forsyth Barr has within the past 12 months been engaged to provide investment banking services to any other issuer referred to in this publication, please refer to the most recent research report for that issuer's financial products.

Not personalised financial advice: The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge.

Disclaimer: This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice to you. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction.

Terms of use: Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.